|
|
Post by peppy on May 5, 2022 6:05:50 GMT -5
|
|
|
|
Post by brentie on May 5, 2022 6:54:25 GMT -5
|
|
|
|
Post by Clement on May 5, 2022 8:56:02 GMT -5
I would like to calculate my own estimate but I don't know how to estimate how much contract manufacturing revenue might have been allowed in 1st quarter. Anybody?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 5, 2022 9:08:03 GMT -5
I would like to calculate my own estimate but I don't know how to estimate how much contract manufacturing revenue might have been allowed in 1st quarter. Anybody? The only quote was from Martine when she said her initial order for DPI would be $5M and that was 3Q21. I don't think MNKD has recognized the order so it could fall into 1Q22 or 2Q22. We don't know. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 5, 2022 9:23:44 GMT -5
I would like to calculate my own estimate but I don't know how to estimate how much contract manufacturing revenue might have been allowed in 1st quarter. Anybody? The only quote was from Martine when she said her initial order for DPI would be $5M and that was 3Q21. I don't think MNKD has recognized the order so it could fall into 1Q22 or 2Q22. We don't know. Remember Mike was asked in 3Q CC when will MNKD expect consistent Revenues from DPI. He said 6 -12 mos. At this time he knew about the pending CRL. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 5, 2022 14:07:31 GMT -5
The only quote was from Martine when she said her initial order for DPI would be $5M and that was 3Q21. I don't think MNKD has recognized the order so it could fall into 1Q22 or 2Q22. We don't know. Remember Mike was asked in 3Q CC when will MNKD expect consistent Revenues from DPI. He said 6 -12 mos. At this time he knew about the pending CRL. It sounds like Martine is being conservative on the conversion rate. I'm sure when patients see the convenience and the increase in dosage they will change over. In all fairness she and the CFO have been all over the place with predictions. Their range was from 50% - 70%. I guess they settled on the midpoint. |
|
|
|
Post by Clement on May 5, 2022 16:07:21 GMT -5
I would like to calculate my own estimate but I don't know how to estimate how much contract manufacturing revenue might have been allowed in 1st quarter. Anybody? Now we know. None of it in Q1. It's deferred. " In August 2021, we entered into a commercial supply agreement (“CSA”) with UT. Revenue associated with the CSA is deferred as of March 31, 2022 and will be recognized over the period when commercial product is sold to UT. The deferred revenue balance associated with the CSA increased by $7.1 million in the first quarter to $25.7 million as of March 31, 2022." investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-first-quarter-financial |
|
|
|
Post by hellodolly on May 5, 2022 16:35:22 GMT -5
Sounds like they have enough cash on hand that rising interest rates aren't going to really impact them. They made some sound decisions over the years to fix their financials.
|
|
|
|
Post by radgray68 on May 5, 2022 16:39:39 GMT -5
So we basically have to endure the expense of manufacturing but can’t get paid for it yet on the books. Some great effed up accounting rules huh? Anything to keep us from showing ANY profitability as long as possible. Add in the FDA has done its best to make sure we don’t make any real money this whole year.
Feel a little like Charlie Brown. Lucy keeps moving the football
|
|
|
|
Post by cedafuntennis on May 5, 2022 16:57:59 GMT -5
Wrong! MNKD is getting paid for the manufacturing, but they cannot recognize it on paper. Hence the loss showing, but the cash is coming in. Listen to the presentation and you will see that they mentioned that at least in two ocassions.
|
|
|
|
Post by boca1girl on May 5, 2022 17:13:32 GMT -5
So we basically have to endure the expense of manufacturing but can’t get paid for it yet on the books. Some great effed up accounting rules huh? Anything to keep us from showing ANY profitability as long as possible. Add in the FDA has done its best to make sure we don’t make any real money this whole year. Feel a little like Charlie Brown. Lucy keeps moving the football We’ll realize it in 2Q if the FDA approves this month. Differed revenue is very common in the software industry, especially with subscriptions. They build it into their revenue estimates throughout the year. Hang in there, patience is key. I’m wondering what the shelf life is, just in case approval is delayed again. |
|
|
|
Post by cedafuntennis on May 5, 2022 18:11:42 GMT -5
Shelf life is not the issue with Afrezza. Share price on the other hand is...
|
|
|
|
Post by buyitonsale on May 5, 2022 18:17:57 GMT -5
In this case, deferred revenue = MNKD is getting paid for manufacturing , but cannot show it as booked revenue yet. They will report it as soon as first product is officially sold to UT.
"from a cash stand point, we were able to invoice and collect from United Therapeutics for these manufacturing activities"
Steven Binder on today's call.
|
|
|
|
Post by nxc2 on May 5, 2022 18:44:34 GMT -5
I think that they will not realize all the revenue at one time - it seems that it will be spread out over the contract period which goes for many years - thought I heard Binder say that.
|
|
|
|
Post by Clement on May 5, 2022 19:59:18 GMT -5
I think that they will not realize all the revenue at one time - it seems that it will be spread out over the contract period which goes for many years - thought I heard Binder say that. maybe months instead of years |
|
